Model cell membrane interaction with a bioinspired amphoteric polymer

We present recent investigation by means of nanoscale techniques on biocompatible linear polyamidoamines with amphoteric character, namely AGMA1 and ARGO7. These polymers have been shown of extremely promising and already proved medical interest, comprising their strong protection actions against virus infection, mainly papilloma and herpes and the extremely low toxicity of their DNA complexes, with respect to other used polymers such as PEI and protamine, applied in nanovector design for gene delivery. Our studies focus on the most important of these polymers, AGMA1, a prevailingly cationic 4-aminobutylguanidine-deriving PAA, whose mechanism of action is so far not fully understood. The current understanding is that its interaction with cell surfaces by means of glycosaminoglycans (HSPG) has a major role in its protective action against viruses. Yet, AGMA1 is active also against HPV-31, whose attachment does not appear to be dependent on HSPG. HPV-31, whose attachment does not appear to be dependent on HSPG. Therefore, AGMA1 binds other (as yet unidentified) receptors on the cell surface. As the known recipient is the HS carbohydrate moiety, other sugars rich membrane components have been proposed as probable AGMA1 target. Therefore, to shed a light on the mechanism of interaction of the polymer with sugar containing biologically relevant molecules, not HS, we have investigated AGMA1 in interaction with glycophyngolipids, Specifically, we studied multicomponent symmetric vesicles enriched in ganglioside GM1 built to mimic biological membrane domains, in the presence of AGMA1, At physiological pH, electrostatic effects should be the relevant interactions between GM1 and AGMA1. Taking advantage of the same mechanism we investigated the possibility of building lipid based core-shell particles to vehiculate AGMA1/siRNA complexes. Moreover, since it is probable that AGMA1 interacts with the barrier of mucus which cover the involved tissue we have extended our investigations also to mucin, constituting the biological barrier to the target tissues of the medical application of the polymers

Interaction of mucins with bioinspired polymers and drug delivery particles

Mucins are glycoproteins with high molecular weight and an abundance of negatively charged oligosaccharide side chains, representing the main components in the mucous gels apart from water. Mucin structure consists of a flexible backbone (mainly serine and threonine residues) which serves as anchoring points for oligosaccharide side chains, and hydrophobic \u201cnaked domains\u201d enriched in cysteine residues. The latter can form inter-molecular bonds via disulphide links, promoting mucin association in solution. Therefore, mucins can establish adhesive interactions with particulates/biomacromolecules via electrostatic interactions, van der Waals forces, hydrophobic forces, hydrogen bonding, or chain entanglement. Mucosal drug delivery vehicles can either penetrate rapidly or establish prolonged contact. However, their development is of great challenge because little is still known about the interactions between mucin and other macromolecules. We are currently working on a comprehensive study of the interaction between mucin and macromolecules of interest for pharmaceutical developments by complementary techniques. To this scope, we employ biocompatible natural and synthetic polymers with different physical-chemical characteristics. Among them, linear polyamidoamines with amphoteric character are particularly interesting for their cyto-biocompatibility. It is indeed crucial to characterise such interactions not only in the bulk but also at the interface, since complexation between mucins and biomacromolecules takes place close to the cell membrane surface. Moreover, the strategy to overcome mucus barrier and achieve long retention time in the cell surface is to develop nano-agents which can effectively penetrate the mucus layer and accumulate at the epithelial surface. In this framework we present preliminary investigations in the bulk by small angle x-ray scattering (SAXS) and at the solid-liquid interface by employing quartz crystal microbalance (QCM-D)

Model cell membrane interaction with a bioinspired amphoteric polymer

We present recent investigation by means of nanoscale techniques on biocompatible linear polyamidoamines with amphoteric character, namely AGMA1 and ARGO7. These polymers have been shown of extremely promising and already proved medical interest, comprising their strong protection actions against virus infection, mainly papilloma and herpes and the extremely low toxicity of their DNA complexes, with respect to other used polymers such as PEI and protamine, applied in nanovector design for gene delivery. Our studies focus on the most important of these polymers, AGMA1, a prevailingly cationic 4-aminobutylguanidine-deriving PAA, whose mechanism of action is so far not fully understood. The current understanding is that its interaction with cell surfaces by means of glycosaminoglycans (HSPG) has a major role in its protective action against viruses. Yet, AGMA1 is active also against HPV-31, whose attachment does not appear to be dependent on HSPG. HPV-31, whose attachment does not appear to be dependent on HSPG. Therefore, AGMA1 binds other (as yet unidentified) receptors on the cell surface. As the known recipient is the HS carbohydrate moiety, other sugars rich membrane components have been proposed as probable AGMA1 target. Therefore, to shed a light on the mechanism of interaction of the polymer with sugar containing biologically relevant molecules, not HS, we have investigated AGMA1 in interaction with glycophyngolipids, Specifically, we studied multicomponent symmetric vesicles enriched in ganglioside GM1 built to mimic biological membrane domains, in the presence of AGMA1, At physiological pH, electrostatic effects should be the relevant interactions between GM1 and AGMA1. Taking advantage of the same mechanism we investigated the possibility of building lipid based core-shell particles to vehiculate AGMA1/siRNA complexes. Moreover, since it is probable that AGMA1 interacts with the barrier of mucus which cover the involved tissue we have extended our investigations also to mucin, constituting the biological barrier to the target tissues of the medical application of the polymers

Mucin Thin Layers : a Model for Mucus-Covered Tissues

The fate of macromolecules of biological or pharmacological interest that enter the mucus barrier is a current field of investigation. Studies of the interaction between the main constituent of mucus, mucins, and molecules involved in topical transmucoidal drug or gene delivery is a prerequisite for nanomedicine design. We studied the interaction of mucin with the bio-inspired arginine-derived amphoteric polymer D,L-ARGO7 by applying complementary techniques. Small angle X-ray scattering in bulk unveiled the formation of hundreds of nanometer-sized clusters, phase separated from the mucin mesh. Quartz microbalance with dissipation and neutron reflectometry measurements on thin mucin layers deposited on silica supports highlighted the occurrence of polymer interaction with mucin on the molecular scale. Rinsing procedures on both experimental set ups showed that interaction induces alteration of the deposited hydrogel. We succeeded in building up a new significant model for epithelial tissues covered by mucus, obtaining the deposition of a mucin layer 20 A\u30a thick on the top of a glycolipid enriched phospholipid single membrane, suitable to be investigated by neutron reflectometry. The model is applicable to unveil the cross structural details of mucus-covered epithelia in interaction with macromolecules within the A\u30a discreteness

Aβ beyond the AD pathology : Exploring the structural response of membranes exposed to nascent aβ peptide

The physiological and pathological roles of nascent amyloid beta (A\u3b2) monomers are still debated in the literature. Their involvement in the pathological route of Alzheimer's Disease (AD) is currently considered to be the most relevant, triggered by their aggregation into structured oligomers, a toxic species. Recently, it has been suggested that nascent A\u3b2, out of the amyloidogenic pathway, plays a physiological and protective role, especially in the brain. In this emerging perspective, the study presented in this paper investigated whether the organization of model membranes is affected by contact with A\u3b2 in the nascent state, as monomers. The outcome is that, notably, the rules of engagement and the resulting structural outcome are dictated by the composition and properties of the membrane, rather than by the A\u3b2 variant. Interestingly, A\u3b2 monomers are observed to favor the tightening of adjacent complex membranes, thereby affecting a basic structural event for cell-cell adhesion and cell motility

Safety and efficacy of non-steroidal anti-inflammatory drugs to reduce ileus after colorectal surgery

Background: Ileus is common after elective colorectal surgery, and is associated with increased adverse events and prolonged hospital stay. The aim was to assess the role of non-steroidal anti-inflammatory drugs (NSAIDs) for reducing ileus after surgery. Methods: A prospective multicentre cohort study was delivered by an international, student- and trainee-led collaborative group. Adult patients undergoing elective colorectal resection between January and April 2018 were included. The primary outcome was time to gastrointestinal recovery, measured using a composite measure of bowel function and tolerance to oral intake. The impact of NSAIDs was explored using Cox regression analyses, including the results of a centre-specific survey of compliance to enhanced recovery principles. Secondary safety outcomes included anastomotic leak rate and acute kidney injury. Results: A total of 4164 patients were included, with a median age of 68 (i.q.r. 57\u201375) years (54\ub79 per cent men). Some 1153 (27\ub77 per cent) received NSAIDs on postoperative days 1\u20133, of whom 1061 (92\ub70 per cent) received non-selective cyclo-oxygenase inhibitors. After adjustment for baseline differences, the mean time to gastrointestinal recovery did not differ significantly between patients who received NSAIDs and those who did not (4\ub76 versus 4\ub78 days; hazard ratio 1\ub704, 95 per cent c.i. 0\ub796 to 1\ub712; P = 0\ub7360). There were no significant differences in anastomotic leak rate (5\ub74 versus 4\ub76 per cent; P = 0\ub7349) or acute kidney injury (14\ub73 versus 13\ub78 per cent; P = 0\ub7666) between the groups. Significantly fewer patients receiving NSAIDs required strong opioid analgesia (35\ub73 versus 56\ub77 per cent; P < 0\ub7001). Conclusion: NSAIDs did not reduce the time for gastrointestinal recovery after colorectal surgery, but they were safe and associated with reduced postoperative opioid requirement

Safety of hospital discharge before return of bowel function after elective colorectal surgery

Background: Ileus is common after colorectal surgery and is associated with an increased risk of postoperative complications. Identifying features of normal bowel recovery and the appropriateness for hospital discharge is challenging. This study explored the safety of hospital discharge before the return of bowel function. Methods: A prospective, multicentre cohort study was undertaken across an international collaborative network. Adult patients undergoing elective colorectal resection between January and April 2018 were included. The main outcome of interest was readmission to hospital within 30 days of surgery. The impact of discharge timing according to the return of bowel function was explored using multivariable regression analysis. Other outcomes were postoperative complications within 30 days of surgery, measured using the Clavien\u2013Dindo classification system. Results: A total of 3288 patients were included in the analysis, of whom 301 (9\ub72 per cent) were discharged before the return of bowel function. The median duration of hospital stay for patients discharged before and after return of bowel function was 5 (i.q.r. 4\u20137) and 7 (6\u20138) days respectively (P < 0\ub7001). There were no significant differences in rates of readmission between these groups (6\ub76 versus 8\ub70 per cent; P = 0\ub7499), and this remained the case after multivariable adjustment for baseline differences (odds ratio 0\ub790, 95 per cent c.i. 0\ub755 to 1\ub746; P = 0\ub7659). Rates of postoperative complications were also similar in those discharged before versus after return of bowel function (minor: 34\ub77 versus 39\ub75 per cent; major 3\ub73 versus 3\ub74 per cent; P = 0\ub7110). Conclusion: Discharge before return of bowel function after elective colorectal surgery appears to be safe in appropriately selected patients